Searching for a New Promising Development-Stage Biotech Firm We Found and Picked This One

Krystal Biotech
Krystal Biotech (KRYS) is a gene therapy firm focused on developing topical intradermal therapeutics for rare dermatological diseases. It developed its a gene therapy product KB103 for the treatment of the broad Dystrophic epidermolysis bullosa (DEB) population, including both recessive and dominant forms of the disease. The vector that introduces the genes into dermal cells is an HSV . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.